Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-Small Lung Cancer

NCT06951399 is registered in ClinicalTrials.gov with Rabin Medical Center as lead sponsor.

NCT NCT06951399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06951399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-Small Lung Cancer
Lead sponsor
Rabin Medical Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
April 30, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc (advanced non-small cell lung cancer), nsclc adenocarcinoma, nsclc stage iv without egfr/alk mutation